Because the function of RUNX1 is often compromised in AML, we asked the question if these mutations might additionally alter RUNX1’s interaction (off-target) with known FDA-approved drug molecules, including three currently used in treating AML. Here, RUNX1 is linked to acute myeloid leukemia.